LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex: BPA) announced today that it has been granted a presentation at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting. The ISSWSH meeting is being held from February 22-25 in Orlando, Florida. BioSante will present information regarding Phase II study results and the initiation of a Phase III safety and efficacy study of LibiGel® (transdermal testosterone gel) in the treatment of female sexual dysfunction (FSD). The six-month, double-blind, placebo-controlled Phase III study is planned to enroll approximately 360 surgically menopausal women and is being conducted under a Phase III protocol and investigational new drug application (IND) reviewed by and on file with the U.S. Food and Drug Administration (FDA).
